参附注射液对肺癌患者化疗后癌因性疲乏的疗效观察

目的:观察参附注射液对肺癌患者化疗后癌因性疲乏的疗效。方法:将182例符合入组条件的肺癌患者随机分为单纯化疗组(对照组,58例)、参附注射液低剂量组(62例)和高剂量组(62例),3组除常规化疗外,低剂量组和高剂量组分别静脉滴注参附注射液30、60mL.d-1。治疗前、后化疗3组均为3周方案,疗程共4个周期。采用Piper疲乏修正量表测量患者的疲乏水平,并观察治疗中出现的不良反应。结果:化疗4周期后,高剂量组的癌因性疲乏水平较对照组和低剂量组均明显降低,且差异有统计学意义(P<0.05);但低剂量组与对照组疲乏水平比较,差异无统计学意义(P>0.05)。研究过程中未发现与用药有关的不良反应。结论:高剂量的参附注射液对肺癌化疗后的癌因性疲乏有减轻作用,且安全性较好。

Efficacy Observation of Shenfu Injection on the Cancer-related Fatigue in Lung Cancer Patients after Che- motherapy

To observe the effects of Shenfu injection on the cancer-related fatigue （CRF）in lung cancer patients after chemotherapy. METHODS： 182 patients with lung cancer were randomly divided into simple chemotherapy group （control group, 58 cases）, low dosage group （62 cases） and high dosage group （62 cases）. Low dosage group and high dosage group re- ceived Shenfu injection 30 mL.d-1 and 60 mL.d-1 via i.v. gtt in addition to conventional chemotherapy. In the study, 3 groups all receined chemotherapy for 3 weeks. Treatment course lasted for 4 weeks. The level and degree of CRF and ADR in each group were determined after chemotherapy. RESULTS： After the 4 cycles, the CRF in high dosage group decreased significantly, com- pared with control group and low dosage group （P〈0.05） ; the low dosage group compared with control group had no difference （P〉0.05）. No ADR related to drug use was found in the research process. CONCLUSION： Shenfu injection can reduce the CRF of chemotherapeutical drugs with low ADR in patients with lung cancer.